Rapt Therapeutics Inc Expected To Post A Loss Of 80 Cents A Share: Earnings Preview

Rapt Therapeutics

08/03/2024 13:13

* RAPT Therapeutics Inc  RAPT.OQ   RAPT.O  is expected
to show no
change in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for RAPT Therapeutics Inc is
for a
loss of 80 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for RAPT
Therapeutics
Inc is $19.50​, above​ its last closing price of $9.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.86       -0.86      -0.80     Beat    6.8
 Sep. 30 2023  -0.75       -0.75      -0.82     Missed  -8.9
 Jun. 30 2023  -0.79       -0.78      -0.66     Beat    15.6​
 Mar. 31 2023  -0.67       -0.68      -0.76     Missed  -11.8
 ​​Dec.        -0.62       -0.65      -0.64     Beat    2.1
 31 2022                                                
 Sep. 30 2022  -0.65       -0.67      -0.63     Beat    6​
 Jun. 30 2022  -0.76       -0.75      -0.62     Beat    17.3
 Mar. 31 2022  -0.66       -0.68      -0.69     Missed  -1.7
 This summary was machine generated March 8 at 13:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)